{"protocolSection":{"identificationModule":{"nctId":"NCT04890366","orgStudyIdInfo":{"id":"haojunwei3"},"organization":{"fullName":"Xuanwu Hospital, Beijing","class":"OTHER"},"briefTitle":"Combination of the Immune Modulator Dimethyl Fumarate With Alteplase in Acute Ischemic Stroke","officialTitle":"Combination of the Immune Modulator Dimethyl Fumarate With Alteplase in Acute Ischemic Stroke"},"statusModule":{"statusVerifiedDate":"2022-06","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-12-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-12-31","type":"ESTIMATED"},"completionDateStruct":{"date":"2022-12-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2021-05-11","studyFirstSubmitQcDate":"2021-05-17","studyFirstPostDateStruct":{"date":"2021-05-18","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-06-02","lastUpdatePostDateStruct":{"date":"2022-06-06","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Xuanwu Hospital, Beijing","class":"OTHER"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The investigators conduct this study to investigate whether oral administration of Dimethyl Fumarate, a Food and Drug Administration-approved drug for multiple sclerosis, is safe and effective in combination with alteplase in patients with Acute Ischemic Stroke."},"conditionsModule":{"conditions":["Acute Ischemic Stroke"],"keywords":["Dimethyl Fumarate","immune modulator","Alteplase","Acute Ischemic Stroke","edema"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","whoMasked":["OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":50,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Alteplase plus Dimethyl Fumarate","type":"EXPERIMENTAL","interventionNames":["Drug: Dimethyl Fumarate"]},{"label":"Alteplase","type":"NO_INTERVENTION"}],"interventions":[{"type":"DRUG","name":"Dimethyl Fumarate","description":"Dimethyl fumarate 240mg orally twice daily for 3 consecutive days","armGroupLabels":["Alteplase plus Dimethyl Fumarate"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"changes in lesion volume","description":"measured by MRI","timeFrame":"baseline to day 7"},{"measure":"changes in hemorrhage volume","description":"measured by MRI","timeFrame":"baseline to day 7"},{"measure":"changes in National Institutes of Health Stroke Scale (NIHSS)","description":"The NIHSS score ranges from 0 to 42 points. The higher the score, the more severe the neurological impairment.","timeFrame":"baseline to day 7"}],"secondaryOutcomes":[{"measure":"The Modified Rankin Scale (mRS)","description":"The mRS score ranges from 0 to 7 points. The higher the score, the more severe the neurological recovery state of stroke patients.","timeFrame":"day1"},{"measure":"The Modified Rankin Scale (mRS)","description":"The mRS score ranges from 0 to 7 points. The higher the score, the more severe the neurological recovery state of stroke patients.","timeFrame":"day3"},{"measure":"The Modified Rankin Scale (mRS)","description":"The mRS score ranges from 0 to 7 points. The higher the score, the more severe the neurological recovery state of stroke patients.","timeFrame":"day7"},{"measure":"The Modified Rankin Scale (mRS)","description":"The mRS score ranges from 0 to 7 points. The higher the score, the more severe the neurological recovery state of stroke patients.","timeFrame":"day14"},{"measure":"The Modified Rankin Scale (mRS)","description":"The mRS score ranges from 0 to 7 points. The higher the score, the more severe the neurological recovery state of stroke patients.","timeFrame":"day90"},{"measure":"National Institutes of Health Stroke Scale (NIHSS)","description":"The NIHSS score ranges from 0 to 42 points. The higher the score, the more severe the neurological impairment.","timeFrame":"day 3"},{"measure":"National Institutes of Health Stroke Scale (NIHSS)","description":"The NIHSS score ranges from 0 to 42 points. The higher the score, the more severe the neurological impairment.","timeFrame":"day 7"},{"measure":"National Institutes of Health Stroke Scale (NIHSS)","description":"The NIHSS score ranges from 0 to 42 points. The higher the score, the more severe the neurological impairment.","timeFrame":"day 14"},{"measure":"National Institutes of Health Stroke Scale (NIHSS)","description":"The NIHSS score ranges from 0 to 42 points. The higher the score, the more severe the neurological impairment.","timeFrame":"day 90"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. more than 18years old\n2. NIHSS scoreâ‰¥5\n3. MRI shows anterior circulation infarction\n4. Patients who meet Alteplase thrombolytic therapy within 4.5h\n5. The time from onset to DMF application was less than 24 hours\n\nExclusion Criteria:\n\n1. Hemorrhagic stroke\n2. Patients who have received or plan to receive endovascular therapy\n3. Other diseases of the central nervous system\n4. Pre-existing neurological disability (mRS Score \\>2)\n5. Vertebrobasilar artery obstruction\n6. Difficulty swallowing\n7. Patients who cannot accept MRI examination\n8. Abnormal liver function (transaminase higher than 2 times the normal upper limit)\n9. The lymphocyte count was lower than the lower limit of normal value\n10. Anti-tumor drugs, other immunosuppressive and immunomodulatory drugs are being used\n11. Patients known to have hypersensitivity to dimethyl fumarate or any excipients\n12. Pregnant and lactating women","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Junwei Hao, PhD,MD","role":"CONTACT","phone":"010-83199270","email":"haojunwei@vip.163.com"}],"overallOfficials":[{"name":"Junwei Hao, PhD,MD","affiliation":"Xuanwu Hospital, Beijing","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Xuanwu Hospital, Capital Medical University","status":"RECRUITING","city":"Beijing","state":"Beijing","zip":"100053","country":"China","contacts":[{"name":"Junwei Hao, PhD,MD","role":"CONTACT","email":"haojunwei@vip.163.com"}],"geoPoint":{"lat":39.9075,"lon":116.39723}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14","submissionTracking":{"estimatedResultsFirstSubmitDate":"2023-10-24","submissionInfos":[{"releaseDate":"2023-10-24"}]}},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M7347","name":"Edema","relevance":"LOW"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069462","term":"Dimethyl Fumarate"}],"ancestors":[{"id":"D000003879","term":"Dermatologic Agents"},{"id":"D000007166","term":"Immunosuppressive Agents"},{"id":"D000007155","term":"Immunologic Factors"},{"id":"D000045505","term":"Physiological Effects of Drugs"}],"browseLeaves":[{"id":"M2854","name":"Immunomodulating Agents","relevance":"LOW"},{"id":"M13539","name":"Tissue Plasminogen Activator","relevance":"LOW"},{"id":"M431","name":"Dimethyl Fumarate","asFound":"Periodontal treatment","relevance":"HIGH"},{"id":"M6764","name":"Dermatologic Agents","relevance":"LOW"},{"id":"M9902","name":"Immunosuppressive Agents","relevance":"LOW"},{"id":"M9891","name":"Immunologic Factors","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"Derm","name":"Dermatologic Agents"}]}},"hasResults":false}